期刊文献+

紫杉醇脂质体联合表阿霉素方案在乳腺癌新辅助化疗中的近期疗效 被引量:3

Short-term Response of Neoadjuvant Chemotherapy with Paclitaxel Liposome and Epirubicin Combination for Breast Cancer
原文传递
导出
摘要 [目的]观察紫杉醇脂质体在乳腺癌新辅助化疗中的疗效、毒副反应。[方法]回顾性分析20例局部晚期乳腺癌患者含紫杉醇脂质体方案新辅助化疗的疗效、毒副作用。化疗方案为紫杉醇脂质体加表阿霉素,21d为一周期,术前化疗2~6个周期,评估肿瘤缓解情况及毒副反应。[结果]化疗有效率为90%,其中CR3例,PR15例,SD1例,PD1例,达pCR1例。[结论]紫杉醇脂质体联合表阿霉素方案在乳腺癌的新辅助化疗中疗效肯定,毒副反应低,值得进一步研究。
出处 《中国肿瘤》 CAS 2008年第12期1086-1088,共3页 China Cancer
  • 相关文献

参考文献9

  • 1Van der Hage JA, van de Velde C J, Julien JP, et al. preoperative chemotherapy in primary operable breast cancer: Results from the European organization for research and treatment of cancer tris10902[J]. J Clin Oncol,2001, 19 (22):4224-4237.
  • 2Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-years results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr, 2001, 30: 96-102.
  • 3Buzdar AU, Singletary SE, Theriauh RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patient with operable breast cancer [J]. J Clin Oncol, 1999, 17 (11):3412- 3417.
  • 4Molitemi A, Tarenzi E, Capri G, et al. Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer[J]. Semin Oncol, 1997, 24(Suppl 17):10-14.
  • 5Garces CA , Cance WG. Neoadjurant chemotherapy of breast cancer [J]. Am Surg, 2004, 70(7): 565-569.
  • 6Kaufmann M, Hortobagyi GN, Goldhirsch A, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update[J]. J Clin Oncol, 2006, 24 (12):1940- 1949.
  • 7Shimizu C, Ando M, Kouno T, et al. Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer [J]. Jpn J Clin Oncol, 2007, 37(1): 1-8.
  • 8Jones RE, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumor response[J]. Lancet Oncol, 2006, 7: 869.
  • 9滕小玉,管忠震,姚志文,刘冬耕,周宁宁,罗汉钰,Michael Hawkins,Patrick Soon-Shiong.晚期实体癌患者对不含聚氧乙烯蓖麻油注射用紫杉醇白蛋白纳米粒悬浮液的临床耐受性研究[J].癌症,2004,23(z1):1431-1436. 被引量:39

二级参考文献22

  • 1[1]Taxol(R) (paclitaxel) Injection [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Co; March 2003
  • 2[2]Lorenz W, Reimann HJ, Schmal A, et al. Histamine release in dogs by Cremophor EL and its derivatives: Oxethylated oleic acid is the most effective constituent [ J]. Agents Actions, 1977, 7 ( 1 ): 63 -67.
  • 3[3]Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation [J]. Eur J Cancer, 2001, 37(13): 1590 - 1598.
  • 4[4]Rowinsky EK, Donehower RC. Paclitaxel (taxol) [J]. N Engl J Med, 1995, 332(15): 1004 - 1014.
  • 5[5]Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to Paclitaxel: an in vitro study [J]. J Natl Cancer Inst, 1998, 90(4):300 - 305.
  • 6[6]ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy [J] .Clin Pharmacokinet, 2003, 42 (7): 665 - 685.
  • 7[7]van Zuylen L, Karlsson MO, Verweij J, et al. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles [J]. Cancer Chemother Pharmacol, 2001, 47(4): 309 - 318.
  • 8[8]Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood:clinical pharmacokinetic implications [J] . Cancer Res, 1999, 59(7): 1454 - 1457.
  • 9[9]Ibrahim NK, Desai N, Legha S, et al. Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free proteinstabilized. nanoparticle formulation of paclitaxel [J]. Clin Cancer Res, 2002, 8(5): 1038 - 1044.
  • 10[10]Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over [J]. J Clin Oncol, 2000, 18(4): 724 - 733.

共引文献38

同被引文献22

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部